Get the Stockscreener App
1.92
1.03%
-0.02
After Hours:
1.98
0.06
+3.13%
Inovio Pharmaceuticals Inc stock is traded at $1.92, with a volume of 593.76K.
It is down -1.03% in the last 24 hours and up +19.25% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$1.94
Open:
$1.97
24h Volume:
593.76K
Relative Volume:
0.92
Market Cap:
$62.71M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-0.3153
EPS:
-6.09
Net Cash Flow:
$-124.69M
1W Performance:
+12.28%
1M Performance:
+19.25%
6M Performance:
-61.21%
1Y Performance:
-83.10%
1-Day Range:
$1.86
$1.97
1-Week Range:
$1.685
$1.97
52-Week Range:
$1.42
$13.44
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.92 | 62.71M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
Inovio Pharmaceuticals (INO) Advances BLA Submission for INO-310 - GuruFocus
Earnings call transcript: Inovio’s Q1 2025 sees narrowed losses, stock rises - Investing.com
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Inovio: Q1 Earnings Snapshot - San Francisco Chronicle
INO Reports Strong Q1 Revenue, Progress on INO-3107 Submission | - GuruFocus
INOVIO Reports First Quarter 2025 Financial Results and Recent B - GuruFocus
Inovio Pharmaceuticals Inc (INO) Q1 2025 Earnings: EPS of -$0.51 - GuruFocus
Inovio Pharmaceuticals Q1 Operating Expenses USD 25.1 Million - marketscreener.com
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire
Inovio Pharmaceuticals (NASDAQ:INO) Lowered to “Sell” Rating by StockNews.com - Defense World
Inovio Pharmaceuticals (INO) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Inovio at The Citizens JMP Life Sciences Conference: DNA Platform Progress - Investing.com Australia
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Sold by Renaissance Technologies LLC - Defense World
Inovio Pharmaceuticals (NASDAQ:INO) Cut to Sell at StockNews.com - Defense World
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 - Kilgore News Herald
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INOVIO to Announce Q1 2025 Results and Host Live Webcast on May 13 - MyChesCo
Geode Capital Management LLC Boosts Stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
INOVIO to Present at Upcoming Scientific and Investor Conferences - The Bradford Era
INOVIO to Present at Upcoming Scientific and Investor Conferences | INO Stock News - GuruFocus
XTX Topco Ltd Acquires New Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
INOVIO Reveals Breakthrough: DNA Therapy INO-3107 Cuts RRP Surgeries by 81%First Long-Term Data - Stock Titan
INOVIO Q1 2025 Earnings: DNA Medicine Leader to Reveal Latest Financial Performance May 13 - Stock Titan
Bank of Montreal Can Makes New $43,000 Investment in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock rises Thursday, still underperforms market - MarketWatch
Human Papillomavirus Market Set for Breakthrough Expansion - openPR.com
Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Bet on These 5 Top-Ranked Stocks With Rising P/E - Nasdaq
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Inovio Pharmaceuticals (NASDAQ:INO) Raised to “Hold” at StockNews.com - Defense World
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial - ADVFN
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference - MSN
INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences - MyChesCo
Inovio (INO) Upgraded to Buy: Here's What You Should Know - MSN
INOVIO Reports Inducement Grant Under Inducement Plan - MarketScreener
Next-generation Covid-19 vaccines currently being tested - Yahoo Finance
INOVIO to Present at Upcoming Scientific Conferences | INO Stock News - GuruFocus
INOVIO to Present at Upcoming Scientific Conferences - Longview News-Journal
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):